CoChat

Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression

Open access
Levy, Marion J. F., Boulle, Fabien, Steinbusch, Harry W., van den Hove, Daniël L. A., Kenis, Gunter, Lanfumey, Laurence · 2018 · Psychopharmacology

The DOI matches its Crossref record; 373 of the 378 references it cites were found in a registry or an index; 122 of the 287 sources its claims cite were checked for support.

Abstract

Depression is a major health problem with a high prevalence and a heavy socioeconomic burden in western societies. It is associated with atrophy and impaired functioning of cortico-limbic regions involved in mood and emotion regulation. It has been suggested that alterations in neurotrophins underlie impaired neuroplasticity, which may be causally related to the development and course of depression. Accordingly, mounting evidence suggests that antidepressant treatment may exert its beneficial effects by enhancing trophic signaling on neuronal and synaptic plasticity. However, current antidepressants still show a delayed onset of action, as well as lack of efficacy. Hence, a deeper understanding of the molecular and cellular mechanisms involved in the pathophysiology of depression, as well as in the action of antidepressants, might provide further insight to drive the development of novel fast-acting and more effective therapies. Here, we summarize the current literature on the involvement of neurotrophic factors in the pathophysiology and treatment of depression. Further, we advocate that future development of antidepressants should be based on the neurotrophin theory.

Overview

CoChat Summary

## TL;DR

This is a narrative review arguing that depression is closely linked to disrupted neuroplasticity and altered neurotrophic signaling, especially in cortico-limbic circuits such as the hippocampus, prefrontal cortex, amygdala, and ventral striatum. The authors conclude that antidepressant development should increasingly target neurotrophin pathways, especially BDNF/TrkB, to achieve faster and more effective treatments.

## Key findings

  • Depression is associated with structural and functional changes in mood-related brain regions, including reduced hippocampal volume, reduced size of multiple PFC areas, altered amygdala activity, and impaired ventral striatal reward processing.
  • The paper states that serum BDNF is “overall lower in depressed patients” in a meta-analysis, and that this was “confirmed by two other meta-analytic efforts”; however, it also says serum BDNF is not a reliable biomarker because of assay variability and unclear relation to brain BDNF.
  • Multiple growth factors are described as altered in MDD and linked to plasticity: FGF1/FGF2 are reported lower in dorsolateral PFC and ACC, VEGF data are described as conflicting in plasma but relevant to SSRI-induced neurogenesis, and IGF-1 is reported as often higher in serum of depressed patients and reduced with effective antidepressant treatment.
  • Antidepressant and stimulation treatments are summarized as having plasticity-related effects, including increased hippocampal volume after 3 years of medication, increased hippocampal volume after ECT, and increased progenitor/dividing cells in dentate gyrus in post-mortem brains treated with nortriptyline and clomipramine.

## Methods

  • Narrative review of the literature, explicitly stating that it “summarize[s] the current literature” on neurotrophic factors and neuroplasticity pathways in depression and treatment.
  • No original sample, cohort, or experimental dataset is reported in the text provided; instead, the paper synthesizes findings from human imaging, post-mortem studies, meta-analyses, and animal/preclinical studies.
  • Main analysis is qualitative synthesis across brain regions, neuroplasticity mechanisms, growth factors, and therapeutic interventions, with conclusions drawn from the accumulated literature rather than a new statistical analysis.

## Limitations

  • The paper itself notes that much of the human evidence on neuroplasticity is indirect because of “methodological limitations” and “ethical constraints.”
  • It states that several peripheral biomarkers are hard to interpret because there is “no evidence that serum BDNF is related to brain BDNF and neuroplasticity,” and similarly that blood levels of other neurotrophins may not reflect brain levels.
  • Evident from the text: this is a non-exhaustive narrative review, so the conclusions depend on the cited literature rather than a systematic search or meta-analysis by the authors.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00213-018-4950-4

Cites

373 of 373 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Summary of the neuroanatomical changes observed in MDD patients. In the MDD brain, the dotted lines correspond to the brain volume in a healthy patient. In the HIP and the dlPFC, the alternative blue and red colors show the discrepancies reported in the different studies regarding their activities in MDD patients. The thinner arrows and lines show reduced connectivity between the regions. dlPFC, dorsolateral prefrontal cortex; vm/vlPFC, ventromedial/ventrolateral prefrontal cortex; HIP, hippocampus; AMY, amygdala; VTA, ventral tegmental area. See text for more details. This illustration was taken from “Servier medical art” (http://www.servier.fr/servier-medical-art)
Fig. 1 Summary of the neuroanatomical changes observed in MDD patients. In the MDD brain, the dotted lines correspond to the brain volume in a healthy patient. In the HIP and the dlPFC, the alternative blue and red colors show the discrepancies reported in the different studies regarding their activities in MDD patients. The thinner arrows and lines show reduced connectivity between the regions. dlPFC, dorsolateral prefrontal cortex; vm/vlPFC, ventromedial/ventrolateral prefrontal cortex; HIP, hippocampus; AMY, amygdala; VTA, ventral tegmental area. See text for more details. This illustration was taken from “Servier medical art” (http://www.servier.fr/servier-medical-art)CC BY · PubMed Central
Fig. 2 Neurotrophin level changes observed in MDD patients with or without antidepressant treatment. Observed changes in neurotrophin levels, in MDD patients whether or not under antidepressant treatment, represented in the different brain areas involved in depression, and in blood (IGF-1 only). The blue color corresponds to a low level of neurotrophin while the red color shows a high level. Arrows with the single strand represent RNA expression changes and arrows with circles protein level changes. PFC, prefrontal cortex; Acc, anterior cingulate cortex; c.brainstem, caudal brainstem; CSF, cerebrospinal fluid; HIP, hippocampus. See text for more details. This illustration was taken from “Servier medical art” (http://www.servier.fr/servier-medical-art)
Fig. 2 Neurotrophin level changes observed in MDD patients with or without antidepressant treatment. Observed changes in neurotrophin levels, in MDD patients whether or not under antidepressant treatment, represented in the different brain areas involved in depression, and in blood (IGF-1 only). The blue color corresponds to a low level of neurotrophin while the red color shows a high level. Arrows with the single strand represent RNA expression changes and arrows with circles protein level changes. PFC, prefrontal cortex; Acc, anterior cingulate cortex; c.brainstem, caudal brainstem; CSF, cerebrospinal fluid; HIP, hippocampus. See text for more details. This illustration was taken from “Servier medical art” (http://www.servier.fr/servier-medical-art)CC BY · PubMed Central
Fig. 3 Neurotrophins increase neuroplasticity through the activation of three main signaling pathways. Neurotrophins bind to their receptors in order to promote three main signaling pathways: the MAPK/ERK, the PI3-K, and the PLCγ signaling cascades. Once activated, they stimulate neuroplasticity, especially synaptic plasticity, neurotransmission and neuronal survival, growth, and differentiation. An increase of neuroplasticity is likely to induce antidepressant effects. BDNF, brain-derived neurotrophic factor; TrkB, tropomyosin-related kinase receptor B; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; GDNF, glial cell line-derived neurotrophic factor; GFRα1, GDNF-family receptor-α; IGF-1, insulin-like growth factor 1; IGF-1R, insulin-like growth factor 1 receptor; NGF, nerve growth factor; TrkA, tropomyosin-related kinase receptor A
Fig. 3 Neurotrophins increase neuroplasticity through the activation of three main signaling pathways. Neurotrophins bind to their receptors in order to promote three main signaling pathways: the MAPK/ERK, the PI3-K, and the PLCγ signaling cascades. Once activated, they stimulate neuroplasticity, especially synaptic plasticity, neurotransmission and neuronal survival, growth, and differentiation. An increase of neuroplasticity is likely to induce antidepressant effects. BDNF, brain-derived neurotrophic factor; TrkB, tropomyosin-related kinase receptor B; FGF, fibroblast growth factor; FGFR, fibroblast growth factor receptor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; GDNF, glial cell line-derived neurotrophic factor; GFRα1, GDNF-family receptor-α; IGF-1, insulin-like growth factor 1; IGF-1R, insulin-like growth factor 1 receptor; NGF, nerve growth factor; TrkA, tropomyosin-related kinase receptor ACC BY · PubMed Central

Verification

Claims the paper makes

100 Valid · 5 Not valid · 78 Not checked · 14 Own results and interpretations

127 more claims · 64 with their cited sources checked

Create a free account to see all 197 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 59
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 373 references

Cited by

See all 309

Metadata

Authors
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L.
Affiliations
  • Inserm (FR)
  • Maastricht University (NL)
Corresponding author
Lanfumey, Laurence
Venue
Psychopharmacology
Published
2018-06-30
Volume
235
Issue
8
Pages
2195-2220
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
OpenAlex
W2810237733
Cited by
308
References
378
Citations by year
2026: 18 · 2025: 66 · 2024: 34 · 2023: 47 · 2022: 46 · 2021: 49 · 2020: 34 · 2019: 12 · 2018: 1
FWCI
2.81
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Psychopharmacology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion, cc-by)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Funders
  • Inserm
  • Agence Nationale de la Recherche (2011-BSV-017-01)
  • Internationale Stichting Alzheimer Onderzoek (12530)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
depression, neurotrophic factors, neuroplasticity, antidepressants, synaptic plasticity, rapid-acting antidepressants, antidepressant mechanism, depression pathophysiology
MeSH terms
Affect, Animals, Antidepressive Agents, Depression, Emotions, Humans, Nerve Growth Factors, Neuronal Plasticity, Signal Transduction, Biomarkers, Treatment Outcome, Brain-Derived Neurotrophic Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-02, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-02 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. https://app.cochat.ai/papers/10.1007/s00213-018-4950-4
The paper
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018). Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology. https://doi.org/10.1007/s00213-018-4950-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.